CN117297997A - High-efficiency skin tightening polypeptide composition and product application thereof - Google Patents
High-efficiency skin tightening polypeptide composition and product application thereof Download PDFInfo
- Publication number
- CN117297997A CN117297997A CN202311595916.1A CN202311595916A CN117297997A CN 117297997 A CN117297997 A CN 117297997A CN 202311595916 A CN202311595916 A CN 202311595916A CN 117297997 A CN117297997 A CN 117297997A
- Authority
- CN
- China
- Prior art keywords
- polypeptide composition
- skin tightening
- polypeptide
- efficiency
- tightening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 134
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 131
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 128
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 claims abstract description 19
- KQEQPUBSXXOUGC-MLCQCVOFSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-acetylpyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(C)=O)C(O)=O KQEQPUBSXXOUGC-MLCQCVOFSA-N 0.000 claims abstract description 15
- QNZANUZIBYJBIN-XSWJXKHESA-N (3s)-3-[[(2s)-2-acetamido-5-amino-5-oxopentanoyl]amino]-4-[[(2s)-1-[[(1s)-1-carboxy-2-(1h-imidazol-5-yl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound NC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 QNZANUZIBYJBIN-XSWJXKHESA-N 0.000 claims abstract description 15
- 229940086540 acetyl tetrapeptide-9 Drugs 0.000 claims abstract description 15
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 14
- 150000001408 amides Chemical class 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims abstract description 11
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical class CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 36
- 229960001544 sulfathiazole Drugs 0.000 claims description 18
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 claims description 17
- 230000002335 preservative effect Effects 0.000 claims description 16
- 239000003755 preservative agent Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 11
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 6
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 6
- VPKKKVKUOKACNC-UHFFFAOYSA-N 2-bromo-2-hydroxy-1-phenylethanone Chemical compound OC(Br)C(=O)C1=CC=CC=C1 VPKKKVKUOKACNC-UHFFFAOYSA-N 0.000 claims description 3
- -1 sulfathiazole modified alpha-bromo-p-hydroxyacetophenone Chemical class 0.000 claims 1
- 230000006872 improvement Effects 0.000 abstract description 37
- IFUIILQWHYHIEK-UHFFFAOYSA-N 2-Ethoxy-4-(4-methyl-1,3-dioxolan-2-yl)phenol Chemical compound C1=C(O)C(OCC)=CC(C2OC(C)CO2)=C1 IFUIILQWHYHIEK-UHFFFAOYSA-N 0.000 abstract description 16
- 239000011148 porous material Substances 0.000 abstract description 16
- 230000003712 anti-aging effect Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 12
- 238000005260 corrosion Methods 0.000 abstract description 8
- 230000002421 anti-septic effect Effects 0.000 abstract description 4
- 230000009759 skin aging Effects 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 91
- 238000012360 testing method Methods 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- LJYOFQHKEWTQRH-UHFFFAOYSA-N 2-bromo-1-(4-hydroxyphenyl)ethanone Chemical compound OC1=CC=C(C(=O)CBr)C=C1 LJYOFQHKEWTQRH-UHFFFAOYSA-N 0.000 description 5
- 102100025323 Integrin alpha-1 Human genes 0.000 description 4
- 239000002390 adhesive tape Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229920000298 Cellophane Polymers 0.000 description 3
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 3
- 102100029425 Hyaluronan synthase 3 Human genes 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 102100022145 Collagen alpha-1(IV) chain Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000901150 Homo sapiens Collagen alpha-1(IV) chain Proteins 0.000 description 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 2
- 108010041341 Integrin alpha1 Proteins 0.000 description 2
- 102100037369 Nidogen-1 Human genes 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000000585 glomerular basement membrane Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 108010008217 nidogen Proteins 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000003998 snake venom Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000004510 Collagen Type VII Human genes 0.000 description 1
- 108010017377 Collagen Type VII Proteins 0.000 description 1
- 101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 102000012355 Integrin beta1 Human genes 0.000 description 1
- 108010022222 Integrin beta1 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102000040577 NodC/HAS family Human genes 0.000 description 1
- 108091075185 NodC/HAS family Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102000019361 Syndecan Human genes 0.000 description 1
- 108050006774 Syndecan Proteins 0.000 description 1
- 102100035721 Syndecan-1 Human genes 0.000 description 1
- 108090000058 Syndecan-1 Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a high-efficiency skin tightening polypeptide composition and application of a product thereof, and relates to the technical field of cosmetics. The high-efficiency skin tightening polypeptide composition is compounded by utilizing different polypeptides, solves the problems of skin aging and relaxation and tightening skin in a multi-target way, and meets the functional requirements of consumers. The high-efficiency skin tightening polypeptide composition provided by the invention comprises at least one of dipeptide diamino Ding Xianbian-based amide diacetate, acetyl tetrapeptide-11, acetyl tetrapeptide-9, hexapeptide-9 and oligopeptide-1, and the prepared high-efficiency skin tightening polypeptide composition has good antiseptic effect, safety performance, anti-aging performance, ultraviolet ray stain performance improvement and pore performance improvement; in addition, the ethyl vanillin propylene glycol acetal is added into the high-efficiency skin tightening polypeptide composition, so that the prepared high-efficiency skin tightening polypeptide composition has better anti-corrosion effect, anti-aging performance, ultraviolet color spot performance improvement and pore performance improvement.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a high-efficiency skin tightening polypeptide composition and application of a product thereof.
Background
In recent years, many cosmetics or skin care products are favored for their delicate skin and rejuvenation effects. Early days, many animal gland and serum extracts have obvious cosmetic and cosmetology effects, but are less and less advocated by people. Over the past few years, more knowledge of the structure and function of the skin has increased the ability of the cosmetic industry to determine whether a formulation is beneficial to the skin.
The skin is compact and elastic, and people can look much younger. The lack of elasticity is mainly due to the reduced synthesis of immobilized proteins and loss of collagen fibers, resulting in collapse of the dermis and epidermis interface, and the formation of fine wrinkles. Wrinkles around the forehead, eyes, orbit and lips of a human face are evidence of aging, which is also a major problem in skin tightening against aging. These fine lines can occur around the age of 30, mainly due to positional pressure and repetitive facial movements.
The peptides are important physiological regulators of human bodies, can comprehensively regulate physiological functions of the human bodies, excite new generation of cells and collagen, and effectively resist aging, but currently, the domestic applicable cosmetic peptides for tightening and anti-wrinkle are limited, only few products focus on tightening and pulling, the applicable choices are less, and the tightening and anti-aging of the compound combination is lack of efficient and target innovation peptide combination. According to the invention, multiple polypeptide compositions are precisely combined through multiple targets, so that the skin tightening and anti-aging effects are precisely achieved, the optimal skin tightening effect can be achieved, and the requirements of consumers are met.
Disclosure of Invention
The invention aims to provide a high-efficiency skin tightening polypeptide composition and application of a product thereof, wherein the high-efficiency skin tightening polypeptide composition has good anti-corrosion effect, safety performance, anti-aging performance, ultraviolet ray color spot performance improvement and pore performance improvement.
The technical scheme adopted by the invention for achieving the purpose is as follows:
a high-efficiency skin-tightening polypeptide composition,
the high-efficiency skin tightening polypeptide composition comprises polypeptide and preservative;
the polypeptide is at least one of dipeptide diamino Ding Xianbian-base amide diacetate, acetyl tetrapeptide-11, acetyl tetrapeptide-9, hexapeptide-9 or oligopeptide-1;
the preservative comprises a p-hydroxyacetophenone derivative.
Dipeptide diamino Ding Xianbian-yl amide diacetate: a neurotransmitter-inhibiting polypeptide that mimics the activity of the snake venom Waglein I, binds to the epsilon subunit of nmAChR to block acetylcholine binding to receptors and to block neuronal excitation transmission.
Acetyl tetrapeptide-11: can effectively stimulate the generation of the Syndecan-1 and XVII collagen, support the cohesion between the cells of the Syndecan and the XVII collagen and the adhesion with DEJ, and is an active peptide specially aiming at epidermis, and the skin restores the cohesion, the resistance and the delicate skin texture.
Acetyl tetrapeptide-9: effectively stimulates the synthesis of the type I collagen and the basal lamina glycan, and participates in the formation and the diameter growth of collagen fibers. It can make collagen exert good function and effectively delay skin aging and relaxation.
Hexapeptide-9: has the same sequence as human collagen IV and XVII, and has multiple repair promoting effects on epidermis, dermis and DEJ.
Oligopeptide-1: oligopeptide-1 is a synthetic peptide consisting of three amino acids glycine, histidine and lysine. Promoting epidermis regeneration, stimulating skin collagen synthesis, and repairing skin barrier.
Specifically, the preparation method of the high-efficiency skin tightening polypeptide composition comprises the following steps: adding polypeptide into deionized water, stirring, mixing, adding antiseptic, and stirring to obtain high-efficiency skin tightening polypeptide composition.
The invention aims to provide a polypeptide high-efficiency skin tightening polypeptide composition and a product application thereof, which utilize different polypeptide compounding to realize multi-target solution of skin aging relaxation and skin tightening, and meet the functional requirements of consumers. The selected 5 peptides have certain repairing and anti-aging effects on the epidermis layer, basal layer, dermis layer and muscle layer of the skin, the raw material composition comprises at least one polypeptide of dipeptide diamino Ding Xianbian-amidodiacetate, acetyl tetrapeptide-11, acetyl tetrapeptide-9, hexapeptide-9 and oligopeptide-1, the raw material composition HAS the skin care functions which are disclosed in the raw material per se, such as exogenesis expression pattern inhibition effect of snake venom peptide, IV type VII collagen promotion of hexapeptide-9, basal membrane glycan of acetyl tetrapeptide-9, proteoglycan of acetyl tetrapeptide-11 and epidermis repair of oligopeptide-1, and the selected specific combination HAS obvious synergistic promotion effect on aspects of skin tightening related proteins, such as HAS3, COL4A1, ITGA1 and the like.
HAS3: hyaluronan synthase 3; the addition of GlcNAc or glcna monosaccharides to nascent hyaluronic acid polymers is catalyzed. Therefore, it is essential for the synthesis of hyaluronic acid, which is a major component of most extracellular matrices, has a structural role in tissue structure, and regulates cell adhesion, migration and differentiation. This is one of the isozymes catalyzing the reaction (by similarity); belonging to the NodC/HAS family.
COL4A1: collagen alpha-1 (IV) chain; type IV collagen is the major structural component of Glomerular Basement Membrane (GBM), forming a "chicken wire" network with laminin, proteoglycans, and entactin/entactin.
ITGA1: integrin alpha-1; integrin alpha-1/beta-1 is a receptor for laminin and collagen. It recognizes the proline hydroxylation sequence G-F-P-G-E-R in collagen. Anchorage-dependent down-regulation of EGF-stimulated cell growth is involved.
Preferably, the above polypeptides are used in an amount of 0.01 to 0.1wt% in the high-potency skin tightening polypeptide composition.
Preferably, the preservative is present in the high-potency skin tightening polypeptide composition in an amount of 0.5-1.2wt%.
Preferably, the preservative further comprises 1,2 hexanediol.
Preferably, the mass ratio of the p-hydroxyacetophenone derivative to 1,2 hexanediol is as follows: 1:1-1.5.
Preferably, the p-hydroxyacetophenone derivative comprises a product of sulfathiazole modification of alpha-bromo-p-hydroxyacetophenone.
The invention also discloses a preparation method of the p-hydroxyacetophenone derivative, which comprises the following steps: the alpha-bromo-p-hydroxyacetophenone and sulfathiazole are adopted to carry out substitution reaction to prepare the p-hydroxyacetophenone derivative.
The invention provides a preparation method of a p-hydroxyacetophenone derivative, which is characterized in that the p-hydroxyacetophenone derivative prepared by substitution reaction of sulfathiazole and alpha-bromo-p-hydroxyacetophenone is used for preparing a high-efficiency skin tightening polypeptide composition, so that the prepared high-efficiency skin tightening polypeptide composition has good anti-corrosion effect, safety performance, anti-aging performance, ultraviolet ray color spot performance improvement and pore performance improvement.
Specifically, the preparation method of the p-hydroxyacetophenone derivative comprises the following steps:
adding sulfathiazole (the mass volume ratio of sulfathiazole to tetrahydrofuran is 1g:25-40 mL) into tetrahydrofuran, stirring and mixing uniformly, adding sodium carbonate, stirring and mixing for 5-10min, then slowly adding a tetrahydrofuran solution of alpha-bromo-p-hydroxyacetophenone with the concentration of 0.45-0.55g/mL, judging the end of the reaction by TLC, filtering, and separating by column chromatography to obtain the p-hydroxyacetophenone derivative.
Preferably, the molar ratio of the sulfathiazole to the sodium carbonate is as follows: 1:0.8-1.5.
Preferably, the molar ratio of the alpha-bromo-hydroxyacetophenone to the sulfathiazole is as follows: 1:0.8-1.3.
The invention also discloses application of the high-efficiency skin tightening polypeptide composition in preparing cosmetics.
The invention also discloses application of the p-hydroxyacetophenone derivative prepared by the preparation method in preparation of cosmetics.
To further enhance the performance of the high potency skin tightening polypeptide composition, the present invention also incorporates ethyl vanillin propylene glycol acetal into the composition.
The invention also discloses a preparation method of the high-efficiency skin tightening polypeptide composition, wherein the ethyl vanillin propylene glycol acetal is added into the high-efficiency skin tightening polypeptide composition, and the ethyl vanillin propylene glycol acetal and the preservative are added simultaneously, so that the prepared high-efficiency skin tightening polypeptide composition has better anti-corrosion effect, anti-aging performance, ultraviolet color spot performance improvement and pore performance improvement.
Preferably, in the high-efficiency skin tightening polypeptide composition, the mass ratio of the polypeptide to the ethyl vanillin propylene glycol acetal is as follows: 1:0.3-0.8.
The invention also discloses application of the ethyl vanillin propylene glycol acetal in preparing a high-efficiency skin tightening polypeptide composition.
The invention also discloses application of the ethyl vanillin propylene glycol acetal in preparing cosmetics.
The beneficial effects of the invention include:
the invention obtains the high-efficiency skin tightening polypeptide composition and the product application thereof, and the high-efficiency skin tightening polypeptide composition utilizes the combination of different polypeptides to realize multi-target solution of skin aging relaxation and tightening of skin, thereby meeting the functional requirements of consumers. The high-efficiency skin tightening polypeptide composition provided by the invention comprises at least one of dipeptide diamino Ding Xianbian-based amide diacetate, acetyl tetrapeptide-11, acetyl tetrapeptide-9, hexapeptide-9 and oligopeptide-1, and the preservative adopts p-hydroxyacetophenone derivatives, so that the prepared high-efficiency skin tightening polypeptide composition has good preservative effect, safety performance, anti-aging performance, ultraviolet color spot improving performance and pore improving performance; in addition, the ethyl vanillin propylene glycol acetal is added into the high-efficiency skin tightening polypeptide composition, so that the prepared high-efficiency skin tightening polypeptide composition has better anti-corrosion effect, anti-aging performance, ultraviolet color spot performance improvement and pore performance improvement.
Therefore, the invention provides a high-efficiency skin tightening polypeptide composition and application of a product thereof, and the high-efficiency skin tightening polypeptide composition has good anti-corrosion effect, safety performance, anti-aging performance, ultraviolet ray color spot performance improvement and pore performance improvement.
Drawings
FIG. 1 is an infrared spectrum test result of a p-hydroxyacetophenone derivative and p-hydroxyacetophenone.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more clear and clear, the technical solutions of the present invention are described in further detail below with reference to the specific embodiments:
example 1:
a method of preparing a high-efficiency skin tightening polypeptide composition comprising: adding polypeptide into deionized water, stirring, mixing, adding antiseptic, and stirring to obtain high-efficiency skin tightening polypeptide composition. Wherein the polypeptide comprises dipeptide diamino Ding Xianbian-based amide diacetate, acetyl tetrapeptide-11, acetyl tetrapeptide-9, hexapeptide-9 and oligopeptide-1, and the dosage ratio of the dipeptide diamino Ding Xianbian-based amide diacetate to the acetyl tetrapeptide-11, the acetyl tetrapeptide-9, the hexapeptide-9 to the oligopeptide-1 is as follows: 1:1:1:1:1; the preservative comprises a p-hydroxyacetophenone derivative and 1,2 hexanediol; the mass ratio of the p-hydroxyacetophenone derivative to the 1,2 hexanediol is as follows: 1:1. The dosage of the polypeptide in the high-efficiency skin tightening polypeptide composition is 0.1wt%; the amount of preservative in the high-potency skin tightening polypeptide composition is 0.5wt%.
A process for the preparation of p-hydroxyacetophenone derivatives comprising the steps of:
adding sulfathiazole (the mass volume ratio of sulfathiazole to tetrahydrofuran is 1g:25 mL) into tetrahydrofuran, stirring and mixing uniformly, adding sodium carbonate, stirring and mixing for 5min, then slowly adding a tetrahydrofuran solution of alpha-bromo-p-hydroxyacetophenone with the concentration of 0.45g/mL, judging the end of the reaction by TLC, filtering, and separating by column chromatography to obtain the p-hydroxyacetophenone derivative. Wherein, the mol ratio of the sulfathiazole to the sodium carbonate is as follows: 1:0.8; the molar ratio of the alpha-bromo-hydroxyacetophenone to the sulfathiazole is as follows: 1:0.8.
Example 2:
the process for preparing a high-potency skin tightening polypeptide composition differs from that of example 1: the polypeptide comprises acetyl tetrapeptide-11, acetyl tetrapeptide-9, hexapeptide-9 and oligopeptide-1, and the dosage ratio of the acetyl tetrapeptide-11, the acetyl tetrapeptide-9, the hexapeptide-9 and the oligopeptide-1 is as follows: 1:1:1:1; the amount of polypeptide in the high-efficiency skin tightening polypeptide composition is 0.1wt%.
Example 3:
the process for preparing a high-potency skin tightening polypeptide composition differs from that of example 1: the polypeptide comprises dipeptide diamino Ding Xianbian-based amide diacetate, hexapeptide-9 and oligopeptide-1, and the dosage ratio of the dipeptide diamino Ding Xianbian-based amide diacetate, the hexapeptide-9 and the oligopeptide-1 is as follows: 1:1:1; the amount of polypeptide in the high-efficiency skin tightening polypeptide composition is 0.1wt%.
Example 4:
the process for preparing a high-potency skin tightening polypeptide composition differs from that of example 1: the polypeptide comprises hexapeptide-9 and oligopeptide-1, and the dosage ratio of the hexapeptide-9 to the oligopeptide-1 is as follows: 1:1; the amount of polypeptide in the high-efficiency skin tightening polypeptide composition is 0.1wt%.
Example 5:
the process for preparing a high-potency skin tightening polypeptide composition differs from that of example 1: the polypeptide comprises a dipeptide diamino Ding Xianbian-yl amide diacetate; the amount of polypeptide in the high-efficiency skin tightening polypeptide composition is 0.1wt%.
Example 6:
the process for preparing a high-potency skin tightening polypeptide composition differs from that of example 1: the polypeptide comprises acetyl tetrapeptide-11; the amount of polypeptide in the high-efficiency skin tightening polypeptide composition is 0.1wt%.
Example 7:
the process for preparing a high-potency skin tightening polypeptide composition differs from that of example 1: the polypeptide comprises acetyl tetrapeptide-9; the amount of polypeptide in the high-efficiency skin tightening polypeptide composition is 0.1wt%.
Example 8:
the process for preparing a high-potency skin tightening polypeptide composition differs from that of example 1: the polypeptide comprises hexapeptide-9; the amount of polypeptide in the high-efficiency skin tightening polypeptide composition is 0.1wt%.
Example 9:
the process for preparing a high-potency skin tightening polypeptide composition differs from that of example 1: the polypeptide comprises oligopeptide-1; the amount of polypeptide in the high-efficiency skin tightening polypeptide composition is 0.1wt%.
Example 10:
the process for preparing a high-potency skin tightening polypeptide composition differs from that of example 1: the p-hydroxyacetophenone derivative is replaced by p-hydroxyacetophenone.
Example 11:
the process for preparing a high-potency skin tightening polypeptide composition differs from that of example 1: adding ethyl vanillin propylene glycol acetal together with a preservative; the mass ratio of the polypeptide to the ethyl vanillin propylene glycol acetal is as follows: 1:0.5.
Example 12:
the method for preparing a high-potency skin tightening polypeptide composition differs from that of example 10: adding ethyl vanillin propylene glycol acetal together with a preservative; the mass ratio of the polypeptide to the ethyl vanillin propylene glycol acetal is as follows: 1:0.5.
Test example 1:
infrared spectroscopy testing
The sample was analyzed and tested by potassium bromide tabletting.
The above test was performed on the p-hydroxyacetophenone derivative and p-hydroxyacetophenone prepared in example 1, and the results are shown in FIG. 1. As can be seen from FIG. 1, the infrared spectrum of the p-hydroxyacetophenone derivative is 1493cm compared with the infrared spectrum of the p-hydroxyacetophenone -1 、1335cm -1 The existence of an infrared characteristic absorption peak of thiazole ring indicates that sulfathiazole participates in the generation reaction of the p-hydroxyacetophenone derivative.
Test example 2:
security test
The method comprises the steps of performing skin irritation test on New Zealand rabbits, dividing the rabbits into 12 groups, 4 rabbits in each group, performing dehairing treatment on the left side and the right side of each rabbit vertebra, coating 0.5g of high-efficiency skin tightening polypeptide composition sample on the dehairing area on the left side, covering with gauze and cellophane, fixing with adhesive tape, wherein the adhesive tape has no irritation, coating no sample on the right side, covering with gauze and cellophane, fixing with adhesive tape, taking as a control, sealing for 4 hours, removing the gauze, the cellophane and the adhesive tape, and flushing with warm water to remove the sample; continuous experiment 14d was performed 1 time a day, and dehairing treatment was performed before each experiment, and red spots and edema of the experimental part of the rabbit after each experiment were recorded and scored. The scoring criteria are shown in table 1.
TABLE 1 skin irritation intensity grading
TABLE 2 average daily skin irritation mean test results for each rabbit
The above test was performed on the high-potency skin tightening polypeptide composition samples prepared in example 1-example 12, and the results are shown in Table 2. As shown in Table 2, the high-efficiency skin tightening polypeptide composition prepared by the invention is safe and has no stimulation to rabbits.
Test example 3:
anti-aging Performance test
120 female volunteers with dark and dry face, dry and rough eyes and skin ages between 30 and 60 years are selected and divided into 12 groups of 10 people, the selected volunteers do not have any history of skin and systemic diseases, the volunteers do not use immunosuppressants and hormone medicines in nearly one month, the volunteers are fixedly smeared with high-efficiency skin tightening polypeptide composition samples on half faces every day, the smearing amount is 1g each time, the volunteers are used once in the morning and evening, the use is continued for 42 days, the volunteers cannot use other skin care products during the period, and then the detection results are expressed in percentage values through a VISIA professional facial image analyzer.
TABLE 3 results of wrinkle improvement test
The above test was performed on the high-potency skin tightening polypeptide composition samples prepared in example 1-example 12, and the results are shown in Table 3. As can be seen from table 3, the improvement rate of wrinkles is improved in example 1 compared with example 10 and example 11 compared with example 12, which indicates that the p-hydroxyacetophenone derivative prepared from sulfathiazole is used for preparing the high-efficiency skin tightening polypeptide composition, so that the high-efficiency skin tightening polypeptide composition has good anti-aging performance; example 11 significantly improves wrinkle improvement compared to example 1, example 12 compared to example 10, demonstrating that the use of ethylvanillin propylene glycol acetal for the preparation of a high-efficiency skin tightening polypeptide composition results in a high-efficiency skin tightening polypeptide composition having good anti-aging properties; example 1 showed an improvement in wrinkle improvement rate as compared with examples 2 to 9, indicating that dipeptide diamino Ding Xianbian-based amide diacetate, acetyl tetrapeptide-11, acetyl tetrapeptide-9, hexapeptide-9 and oligopeptide-1 had a synergistic effect in anti-aging.
Test example 4:
ultraviolet stain improvement test
The test method was the same as in test example 3.
TABLE 4 ultraviolet stain improvement test results
The above test was performed on the high-potency skin tightening polypeptide composition samples prepared in example 1-example 12, and the results are shown in Table 4. As can be seen from table 4, the improvement rate of ultraviolet spots is improved in example 1 compared with example 10 and example 11 compared with example 12, which indicates that the p-hydroxyacetophenone derivative prepared from sulfathiazole is used for preparing the high-efficiency skin tightening polypeptide composition, so that the high-efficiency skin tightening polypeptide composition has good improvement performance of ultraviolet spots; compared with example 1 and example 12 and example 10, the ultraviolet stain improvement rate is obviously improved, which indicates that when the ethyl vanillin propylene glycol acetal is used for preparing the high-efficiency skin tightening polypeptide composition, the high-efficiency skin tightening polypeptide composition has good ultraviolet stain improvement performance; example 1 showed an improvement in the improvement rate of ultraviolet ray spots as compared with examples 2 to 9, and demonstrated that the dipeptide diamino Ding Xianbian-based amide diacetate, acetyl tetrapeptide-11, acetyl tetrapeptide-9, hexapeptide-9 and oligopeptide-1 had a synergistic effect in improving ultraviolet ray spots.
Test example 5:
pore improvement test
The test method was the same as in test example 3.
TABLE 5 test results of pore improvement
The above test was performed on the high-potency skin tightening polypeptide composition samples prepared in example 1-example 12, and the results are shown in Table 5. As can be seen from table 5, the pore improvement rate of example 1 is improved compared with example 10 and example 11 compared with example 12, which indicates that the p-hydroxyacetophenone derivative prepared from sulfathiazole is used for preparing the high-efficiency skin tightening polypeptide composition, so that the high-efficiency skin tightening polypeptide composition has good pore improvement performance; compared with example 1 and example 12 and example 10, the pore improvement rate is obviously improved, which shows that when the ethyl vanillin propylene glycol acetal is used for preparing the high-efficiency skin tightening polypeptide composition, the high-efficiency skin tightening polypeptide composition has good pore improvement performance; example 1 showed an improvement in pore improvement over examples 2 to 9, indicating that dipeptide diamino Ding Xianbian-based amide diacetate, acetyl tetrapeptide-11, acetyl tetrapeptide-9, hexapeptide-9 and oligopeptide-1 had a synergistic effect in pore improvement.
Test example 6:
corrosion resistance test
Adding 20g of high-efficiency skin tightening polypeptide composition sample into 0.2g of staphylococcus aureus bacterial suspension, stirring and mixing uniformly, and inoculating staphylococcus aureusIs 5X 10 in initial concentration 6 CFU/mL, after 7d incubation at 25℃the microorganism concentration was measured by plate counting.
TABLE 6 test results of corrosion resistance
The above test was performed on the high-potency skin tightening polypeptide composition samples prepared in example 1 and examples 10-12, and the results are shown in Table 6. As can be seen from Table 6, the total number of colonies is significantly reduced in example 1 compared with example 10 and example 11 compared with example 12, which indicates that the p-hydroxyacetophenone derivative prepared from sulfathiazole has good antiseptic effect when used for preparing the high-efficiency skin tightening polypeptide composition; the decrease in colony count in example 11 compared with example 1 and example 12 compared with example 10 suggests that the addition of ethyl vanillin propylene glycol acetal contributes to the improvement of the preservative effect of the high-efficiency skin tightening polypeptide composition.
The conventional technology in the above embodiments is known to those skilled in the art, and thus is not described in detail herein.
The foregoing is merely illustrative of the present invention, and the present invention is not limited thereto, and any person skilled in the art will readily recognize that variations or substitutions are within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims (9)
1. A high-potency skin tightening polypeptide composition, characterized in that:
the high-potency skin tightening polypeptide composition comprises a polypeptide and a preservative;
the polypeptide is at least one of dipeptide diamino Ding Xianbian-base amide diacetate, acetyl tetrapeptide-11, acetyl tetrapeptide-9, hexapeptide-9 or oligopeptide-1;
the preservative comprises a p-hydroxyacetophenone derivative.
2. A high potency skin tightening polypeptide composition according to claim 1, characterized in that: the dosage of the polypeptide in the high-efficiency skin tightening polypeptide composition is 0.01-0.1wt%.
3. A high potency skin tightening polypeptide composition according to claim 1, characterized in that: the preservative is used in an amount of 0.5 to 1.2wt% of the high-potency skin tightening polypeptide composition.
4. A high potency skin tightening polypeptide composition according to claim 1, characterized in that: the preservative further comprises 1,2 hexanediol.
5. The high potency skin tightening polypeptide composition according to claim 4, wherein: the mass ratio of the p-hydroxyacetophenone derivative to the 1,2 hexanediol is as follows: 1:1-1.5.
6. A high potency skin tightening polypeptide composition according to claim 1, characterized in that: the p-hydroxyacetophenone derivative comprises a product of sulfathiazole modified alpha-bromo-p-hydroxyacetophenone.
7. The high potency skin tightening polypeptide composition according to claim 6, wherein: the molar ratio of the alpha-bromo-hydroxyacetophenone to the sulfathiazole is as follows: 1:0.8-1.3.
8. Use of the high-potency skin tightening polypeptide composition as claimed in any one of claims 1-5 in the preparation of a cosmetic.
9. Use of a p-hydroxyacetophenone derivative according to any one of claims 6 to 7 for the preparation of cosmetics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311595916.1A CN117297997B (en) | 2023-11-28 | 2023-11-28 | High-efficiency skin tightening polypeptide composition and product application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311595916.1A CN117297997B (en) | 2023-11-28 | 2023-11-28 | High-efficiency skin tightening polypeptide composition and product application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117297997A true CN117297997A (en) | 2023-12-29 |
| CN117297997B CN117297997B (en) | 2024-03-19 |
Family
ID=89255560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311595916.1A Active CN117297997B (en) | 2023-11-28 | 2023-11-28 | High-efficiency skin tightening polypeptide composition and product application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117297997B (en) |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013064583A1 (en) * | 2011-11-04 | 2013-05-10 | Lipotec, S.A. | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions |
| CN105147534A (en) * | 2015-08-28 | 2015-12-16 | 深圳市维琪医药研发有限公司 | Polypeptide composition for skin repairing |
| CN110585052A (en) * | 2019-10-15 | 2019-12-20 | 上海龙禧投资有限公司 | Composition for anti-wrinkle of periocular skin |
| CN110731924A (en) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | Enhanced anti-aging cosmetic compositions |
| CN111514041A (en) * | 2020-05-20 | 2020-08-11 | 广州市美夫兰化妆品有限公司 | Firming, wrinkle-removing and skin-beautifying lotion and preparation method thereof |
| CN112603857A (en) * | 2020-12-24 | 2021-04-06 | 合肥天一生物技术研究所有限责任公司 | Antioxidant and anti-aging essence |
| KR20210090731A (en) * | 2010-06-09 | 2021-07-20 | 리포텍 에스.에이. | Skin antiaging treatment |
| CN115400043A (en) * | 2022-08-04 | 2022-11-29 | 广州环亚化妆品科技股份有限公司 | Anti-wrinkle composition, preparation method thereof and application thereof in cosmetics |
| CN116077369A (en) * | 2023-03-09 | 2023-05-09 | 润辉生物技术（威海）有限公司 | Composition for removing wrinkles and plumping skin and preparation method and application thereof |
| CN116637042A (en) * | 2023-06-15 | 2023-08-25 | 广州环亚化妆品科技股份有限公司 | Wrinkle-removing anti-aging skin care product and preparation method and application thereof |
| EP4238549A1 (en) * | 2022-03-02 | 2023-09-06 | Galenic Cosmetics Laboratory | Anti-aging composition, skin care product and cosmetic |
| CN116889519A (en) * | 2023-08-21 | 2023-10-17 | 广州市传祺天然化妆品制造有限公司 | Composite polypeptide composition applied to cosmetics and preparation method thereof |
| CN116942559A (en) * | 2022-04-20 | 2023-10-27 | 华熙生物科技股份有限公司 | Smearing type wrinkle-removing composition and application thereof |
-
2023
- 2023-11-28 CN CN202311595916.1A patent/CN117297997B/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210090731A (en) * | 2010-06-09 | 2021-07-20 | 리포텍 에스.에이. | Skin antiaging treatment |
| WO2013064583A1 (en) * | 2011-11-04 | 2013-05-10 | Lipotec, S.A. | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions |
| CN105147534A (en) * | 2015-08-28 | 2015-12-16 | 深圳市维琪医药研发有限公司 | Polypeptide composition for skin repairing |
| CN110731924A (en) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | Enhanced anti-aging cosmetic compositions |
| CN110585052A (en) * | 2019-10-15 | 2019-12-20 | 上海龙禧投资有限公司 | Composition for anti-wrinkle of periocular skin |
| CN111514041A (en) * | 2020-05-20 | 2020-08-11 | 广州市美夫兰化妆品有限公司 | Firming, wrinkle-removing and skin-beautifying lotion and preparation method thereof |
| CN112603857A (en) * | 2020-12-24 | 2021-04-06 | 合肥天一生物技术研究所有限责任公司 | Antioxidant and anti-aging essence |
| EP4238549A1 (en) * | 2022-03-02 | 2023-09-06 | Galenic Cosmetics Laboratory | Anti-aging composition, skin care product and cosmetic |
| CN116942559A (en) * | 2022-04-20 | 2023-10-27 | 华熙生物科技股份有限公司 | Smearing type wrinkle-removing composition and application thereof |
| CN115400043A (en) * | 2022-08-04 | 2022-11-29 | 广州环亚化妆品科技股份有限公司 | Anti-wrinkle composition, preparation method thereof and application thereof in cosmetics |
| CN116077369A (en) * | 2023-03-09 | 2023-05-09 | 润辉生物技术（威海）有限公司 | Composition for removing wrinkles and plumping skin and preparation method and application thereof |
| CN116637042A (en) * | 2023-06-15 | 2023-08-25 | 广州环亚化妆品科技股份有限公司 | Wrinkle-removing anti-aging skin care product and preparation method and application thereof |
| CN116889519A (en) * | 2023-08-21 | 2023-10-17 | 广州市传祺天然化妆品制造有限公司 | Composite polypeptide composition applied to cosmetics and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117297997B (en) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109998953A (en) | It is a kind of for improving the polypeptide Essence of skin quality | |
| CN111544437A (en) | Preparation method and application of 3, 6-anhydro-L-galactose | |
| CN109549893B (en) | Composition and essence milk with blue light pollution resistance and repair effects and preparation method of essence milk | |
| CN114917139B (en) | Compound acetyl hexapeptide-1, transdermal preparation and application thereof | |
| CN114262667A (en) | Novel aureobasidium pullulans strain and application thereof | |
| CN113648235A (en) | Composition for instantly removing wrinkles, eye mask essence, wrinkle removing cosmetic and application | |
| CN115554220B (en) | Microbial fermentation stock solution with skin care effect and preparation method and application thereof | |
| CN114836488B (en) | Anti-wrinkle repair composition containing polypeptide and preparation method thereof | |
| CN117297997B (en) | High-efficiency skin tightening polypeptide composition and product application thereof | |
| WO2013023873A1 (en) | Method for producing 4-aminobutyric acid from algae | |
| CN108210442A (en) | Skin care compositions of mild high nutrition and its preparation method and application | |
| CN115737470B (en) | Carnosine-PDRN compound and preparation method and application thereof | |
| CA2456703C (en) | Method of skin exfoliation with the use of a phosphosugar | |
| KR102211099B1 (en) | A cosmetic composition for improving skin condition comprising functional lipopeptides | |
| KR101753874B1 (en) | A cosmetic composition comprising a decapeptide as an active ingredient | |
| WO2009106934A1 (en) | Angico-branco (piptadenia colubrina) extracts for use in cosmetic and dermatological formulations | |
| EP4197522A1 (en) | Composition comprising galactinol and use thereof | |
| AU2002324634A1 (en) | Method of skin exfoliation | |
| JP7002915B2 (en) | External skin preparation containing Saccharomyces yeast fermented liquid of collagen | |
| CN115154363A (en) | Mulberry resource oligosaccharide moisturizing composition and preparation method and application thereof | |
| KR20180124438A (en) | Cosmetic composition comprising oligo-hyaluronic acid exhibiting up-regulation of aquaporin-3 and anti-inflammatory effect | |
| CH716228B1 (en) | Cosmetic composition in the form of an oil-in-water emulsion revitalizing and toning the skin and lips. | |
| CN109010113B (en) | Composition for repairing sensitive skin and application thereof | |
| CN113952248B (en) | Polypeptide composition and application thereof | |
| CN118304226B (en) | Barrier repairing composition containing camellia chrysantha extract, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |